Coulter Partners successfully completed a search assignment for QBiotics and is pleased to announce the placement of Sergio Duchini as Non-executive Director.

QBiotics is an unlisted public Australian life sciences company that specializes in the discovery and development of novel small molecules to treat complex medical conditions. Its current therapeutic focus is on oncology and wound healing. The Company also has an early-stage antibiotics program.

Sergio Duchini is a seasoned executive with over 30 years of experience across biotechnology, healthcare, and technology. He chairs Neurizon Therapeutics and is a Non-executive Director for Enlitic Inc. Previously, he held leadership roles at Lymphoma Australia, AusBiotech, and was a Deloitte Tax Partner for 23 years, advising on innovation and M&A. Sergio is recognized for strategic leadership and governance expertise.

Commenting on his appointment, Mr. Duchini said: “I’m delighted to be joining the Board of QBiotics at this important stage in its history. I have long admired QBiotics’ pioneering science and have been impressed by the strength of its innovation platform, translational capability, and commitment to delivering real-world impact. I look forward to contributing to QBiotics’ continued growth and global aspirations.”

QBiotics’ Chair, Mark Fladrich said of the appointment, “On behalf of my fellow directors, we are delighted to welcome Sergio to the Board of QBiotics. His deep experience across biotechnology, healthcare and professional services, combined with his proven governance and strategic insights will be invaluable in supporting our clinical and commercial progress.”

Mr. Fladrich added: “We're grateful to Coulter Partners for their ongoing support and expertise. Their consistent success in identifying top-tier talent in the Asia-Pacific region is unparalleled. Having already placed our CEO and several Non-executive Directors, including myself, they have a strong understanding of our needs and have played a key role in helping build the right skillset across our leadership team.”

----

Sergio Duchini, Non-executive Director

Sergio Duchini brings more than 30 years of executive and board-level experience spanning biotechnology, healthcare, technology, and professional services. He currently serves as Non-executive Chair of Neurizon Therapeutics Limited (ASX: NUZ), a clinical-stage biotech company advancing NUZ-001 for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. He is also a Non-executive Director and Chair of the Audit and Risk Committee for Enlitic Inc (ASX: ENL), an AI-driven medical imaging business.

Sergio’s previous governance roles include serving as Chair of Lymphoma Australia (2019–2024), Non-executive Director and Risk & Audit Committee Chair of AusBiotech, and a former Board Member of Deloitte Australia, where he chaired the Remuneration Committee and was a member of the National Diversity and Inclusion Council. He also has over 30 years of professional services experience, including 23 years as a Deloitte Tax Partner. During his tenure at Deloitte, he advised on innovation strategy, R&D investments, and M&A and played an important role in the integration of Deloitte Asia Pacific.

A Chartered Accountant, Chartered Tax Adviser, and Graduate of the Australian Institute of Company Directors, Sergio is recognized for his strategic leadership, commitment to governance excellence, and expertise in innovation, commercialization, and translational research.

About QBiotics

QBiotics is an unlisted, public, Australian life sciences company that seamlessly connects scientific discovery, development and commercialization to harness the power of nature to treat diseases of high unmet need. 
Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds. We also have an early-stage antibiotics program.
QBiotics’ lead molecule, tigilanol tiglate, is a novel, small molecule with the potential to treat a broad range of solid tumors. It is currently in Phase II clinical trials in two indications: soft tissue sarcoma (STS) and head and neck cancer (HNC). Tigilanol tiglate was granted Orphan Drug Designation by the US FDA for the treatment of STS in February 2024.
A veterinary formulation of tigilanol tiglate (STELFONTA®) is approved for the treatment of canine mast cell tumors (MCTs), in major global markets, including the USA, Europe, and Australia. QBiotics has partnered with Virbac, a global animal health company, to distribute STELFONTA®.
Our wound healing drug candidate, EBC-1013, is a small molecule, which targets multiple pathways to accelerate healing, improving outcomes in chronic and acute wounds and burns. A first-in-human Phase I clinical trial in venous leg ulcers is open for recruitment.

www.qbiotics.com

About Coulter Partners

We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.

www.coulterpartners.com

Coulter Partners places Non-executive Director at Australian life sciences company, QBiotics Group Ltd

About QBiotics

About Coulter Partners

Related

19th Bioshares Biotech Summit

Coulter Partners: Fostering Digital Health connections on the Seine

Building better Boards: Key challenges and insights for scaling companies

Coulter Partners joins key discussion on HealthTech Boards at NHS Innovation Accelerator day